NewslettersPulmonary Cell News Neoadjuvant Nivolumab with or without Relatlimab in Resectable Non-Small-Cell Lung Cancer: A Randomized Phase II Trial By Noshin Noorjahan - April 30, 2024 0 In this ongoing, open-label Phase II study, 60 biomarker-unselected, treatment-naive patients with resectable NSCLC were randomized to receive two preoperative doses of nivolumab with or without relatlimab antibody therapy. [Nature Medicine] Full Article